Table 2 Clinical summary of t-AML/t-MDS patients
From: Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential
|  | T-AML/t-MDS sequencing cohort | Overall (n = 134) | Exome (n = 20) | Targeted (n = 92) |
|---|---|---|---|---|
 Age | Median (range) (years) | 62.0 (18–85) | 61.5 (24–80) | 63.0 (18–85) |
Gender | Male | 44.0% | 40.0% | 46.7% |
Female | 56.0% | 60.0% | 53.3% | |
Prior disease | Non-Hodgkin lymphoma | 29.9% | 50.0% | 29.3% |
Breast | 27.6% | 20.0% | 25.0% | |
Gastrointestinal | 6.0% | 5.0% | 7.6% | |
Hodgkin disease | 5.2% | 5.0% | 6.5% | |
Prostate | 5.2% | 0.0% | 6.5% | |
Testicular | 4.5% | 0.0% | 5.4% | |
Other | 21.6% | 20.0% | 19.6% | |
Known previous treatment | Alkylator | 57.5% | 65.0% | 58.7% |
Topoisomerase II inhibitor | 50.7% | 45.0% | 48.9% | |
Platinum | 20.9% | 20.0% | 21.7% | |
Radiation | 65.7% | 65.0% | 65.2% | |
Unknown | 8.2% | 15.0% | 5.4% | |
Latency | Median (range) (years) | 6.1 (0.7–31) | 6.8 (2.5–15.9) | 6.2 (0.7–31) |
Diagnosis | AML | 50.0% | 40.0% | 40.2% |
MDS | 50.0% | 60.0% | 59.8% | |
Cytogenetics | Deletion 5 | 29.9% | 55.0% | 30.4% |
Deletion 7 | 33.6% | 70.0% | 32.6% | |
Complex | 41.0% | 70.0% | 39.1% | |
MLL abnormality | 10.4% | 5.0% | 8.7% | |
Other/unknown | 38.8% | 0.0% | 41.3% | |
% blasts in the bone marrow | Median (range) (%) | 14 (0–95) | 8 (1–80) | 9 (0–91) |
Most intensive treatment regimen | Allogeneic transplant | 37.3% | 30.0% | 41.3% |
Myeloablative | 21.6% | 30.0% | 15.2% | |
Non-myeloablative | 30.6% | 30.0% | 34.8% | |
Other/unknown | 10.4% | 10.0% | 8.7% | |
Remission | Yes | 49.3% | 30.0% | 53.3% |
No | 48.5% | 70.0% | 45.7% | |
Unknown | 2.2% | 0.0% | 1.1% | |
Overall survival | Median (range) (days) | 385 (6–3427) | 187.5 (32–3427) | 424 (6–2432) |
